|
|
| 04 April 2005 |
 |
Paul Martini Prize 2005
Award ceremony
Kurhaus Wiesbaden, Muschelsaal
|
|
| 29 September 2005 |
|
Workshop 2005
Impacts of the 12th Amendment to the German Drugs Law on clinical research in Germany - Conclusions after one year
Berlin
For those affected, this workshop is meant to provide an open forum for exchange on both improvements and problems associated with the new regulations on clinical research included in the 12th Amendment to the German Drugs Law.
program
site plan
registration (waiting list)
|
|
| 21 Oktober 2005 |
|
Paul-Martini-Symposium
Nutzenbewertung von Arzneimitteln - Auswirkungen auf medizinische Leitlinien
Berlin, Kaiserin-Friedrich-Haus
Die Nutzenbewertungen von Arzneimitteln sollen Aussagen über deren Beitrag zur Verbesserung der medizinischen Behandlung von Patienten ermöglichen. Welche Auswirkungen dies auf medizinische Leitlinien haben könnte, soll auf diesem eintägigen Symposium der Paul-Martini-Stiftung diskutiert werden.
Programm
Press-Release
Lageplan
Anmeldung
|
|
|
| 04 November 2005 |
|
Satellitensymposium 2005
im Rahmen des 7. Jahreskongresses für Klinische Pharmakologie, Dresden
Finanzierung von Neuentwicklungen im Gesundheitswesen angesichts der demografischen Entwicklung
|
|
|
| 11/12 November 2005 |
|
Paul-Martini-Symposium 2005
THERAPEUTIC OPPORTUNITIES WITH MONOCLONAL ANTIBODIES - CURRENT STATUS AND PROSPECTS
Berlin
Thirty years ago, on January 23, 1975, Georges Köhler recorded the key experiment for the first ever generation of a monoclonal antibody in his laboratory notebook. Today, therapy with monoclonal antibodies is one of the fastest growing therapeutic areas, both from a medical and economic standpoint. Since the first monoclonal antibody received marketing authorization in 1986, additional ones were created for diagnostics and therapy that can be used predominantly for cancer but also for a number of other serious diseases. The symposium will provide an assessment of the current situation and the prospects of this research area that is already making a key impact on today's therapeutic spectrum.
Preliminary Program
Summary
Map
Registration
|
|
|
| | | | | | | |
|
|
